Copies of extracts of Standalone Unaudited Financial Results of the Company for the quarter ended June 30, 2025 in Business Standard (English Newspaper) all editions and Telugu Prabha (Telugu ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zenotech Laboratories has published its standalone unaudited financial results for Q1 FY26 (quarter ended June 30, 2025) in Business Standard and Telugu Prabha, as required under SEBI Regulation 33. Total income from operations stood at Rs. 1,023.16 lakh, slightly lower than Rs. 1,024.96 lakh in the same quarter last year and down from Rs. 1,262.41 lakh in Q4 FY25. Net profit before exceptional items and tax was Rs. 127.68 lakh versus Rs. 204.55 lakh in Q1 FY25, while net profit after tax came in at Rs. 98.96 lakh versus Rs. 128.97 lakh year-on-year. Basic and diluted EPS was Rs. 0.16 per share (face value Rs. 10) compared with Rs. 0.21 in the year-ago quarter. The results were reviewed by the Audit Committee and approved by the Board on July 28, 2025, and signed by Chairman Azadar Hussain Khan.
Revenue is roughly flat year-on-year, but profit has declined meaningfully versus Q1 FY25, which may be viewed negatively by investors. The filing is a regulatory newspaper publication of already-disclosed results, so no fresh information beyond the Q1 numbers is being introduced.